<code id='737682FE9B'></code><style id='737682FE9B'></style>
    • <acronym id='737682FE9B'></acronym>
      <center id='737682FE9B'><center id='737682FE9B'><tfoot id='737682FE9B'></tfoot></center><abbr id='737682FE9B'><dir id='737682FE9B'><tfoot id='737682FE9B'></tfoot><noframes id='737682FE9B'>

    • <optgroup id='737682FE9B'><strike id='737682FE9B'><sup id='737682FE9B'></sup></strike><code id='737682FE9B'></code></optgroup>
        1. <b id='737682FE9B'><label id='737682FE9B'><select id='737682FE9B'><dt id='737682FE9B'><span id='737682FE9B'></span></dt></select></label></b><u id='737682FE9B'></u>
          <i id='737682FE9B'><strike id='737682FE9B'><tt id='737682FE9B'><pre id='737682FE9B'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:2
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          What's changing in Medicare's open enrollment this year?
          What's changing in Medicare's open enrollment this year?

          AdobeIt’sthemiddleofOctober—thetimeofyearthat’sfilledwithpumpkinspicelattes,jumbo-sizedbagsofHallowe

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Massive project maps cells in human brain in unprecedented detail

          AdobeThebrainremainsboththebody’smostimportantorgananditsleastunderstood.Butadraftatlasofthehumanbra